Last reviewed · How we verify
Biological check-up
Biological check-up is a Biologic drug developed by Centre Hospitalier Universitaire Dijon. It is currently in Phase 3 development for General health screening.
Biological check-up involves the examination of various bodily fluids and tissues to identify potential health issues.
A biological check-up typically involves clinical examination and the collection of biological samples for research purposes. The purpose of a biological check-up can vary, including the assessment of conditions such as COVID-19, epithelial ovarian cancer, and neurological diseases.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Biological check-up |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Modality | Biologic |
| Therapeutic area | General Health |
| Phase | Phase 3 |
Mechanism of action
This process typically includes blood tests, imaging studies, and other diagnostic procedures to assess organ function and detect diseases. The results of the biological check-up help healthcare professionals identify potential health problems and develop a treatment plan.
Approved indications
- General health screening
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (PHASE3)
- Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda (PHASE2)
- Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (PHASE2)
- Natural History Study of Early Life Exposures in Agriculture (ELEA)
- Development of a Neuronal Microscope (NA)
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) (PHASE2)
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological check-up CI brief — competitive landscape report
- Biological check-up updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Dijon portfolio CI
Frequently asked questions about Biological check-up
What is Biological check-up?
How does Biological check-up work?
What is Biological check-up used for?
Who makes Biological check-up?
What development phase is Biological check-up in?
Related
- Manufacturer: Centre Hospitalier Universitaire Dijon — full pipeline
- Therapeutic area: All drugs in General Health
- Indication: Drugs for General health screening
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing